CD38 as a multifaceted immunotherapeutic target in CLL-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD38 as a multifaceted immunotherapeutic target in CLL

Published:2022-08-17 Issue:10 Volume:63 Page:2265-2275
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Paulus Aneel¹²^ORCID,Malavasi Fabio³⁴^ORCID,Chanan-Khan Asher¹²

Affiliation:

1. Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, USA

2. Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA

3. Dipartimento Scienze Mediche, Università di Torino, Torino, Italy

4. Fondazione Ricerca Molinette ONLUS, Università di Torino, Torino, Italy

Funder

National Cancer Institute

National Institutes of Health

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2090551

Reference111 articles.

1. Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

2. A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline

3. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels

4. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism

5. CD38-dependent ADP-ribosyl cyclase activity in developing and adult mouse brain

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of the role of purinergic signaling and insights into its role in cancer therapy;Pharmacology & Therapeutics;2024-10

2. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS;Experimental Oncology;2023-12-28

3. Advances in Monitoring and Prognostication for Lymphoma by Flow Cytometry;Clinics in Laboratory Medicine;2023-09

4. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors;Frontiers in Immunology;2022-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3